6-溴-5-硝基靛红 | 667463-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-溴-5-硝基靛红
• 英文名称: 6-Bromo-5-nitroisatin
• 英文别名: 6-bromo-5-nitro-1H-indole-2,3-dione
• CAS: 667463-68-5
• 化学式: C₈H₃BrN₂O₄
• 分子量: 271.027
• InChiKey: VRQRWHLIXOADMM-UHFFFAOYSA-N

物化性质

• 熔点：
  251-253 °C
• 密度：
  1.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-溴-5-硝基靛红 在 吡啶 、 盐酸羟胺 、 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 6-Bromo-5-nitroindirubin-3'-acetoxime
  参考文献：
  名称：

  Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

  摘要：

  Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.

  DOI：

  10.1021/jm031016d
• 作为产物：
  描述：

  N-(3-bromophenyl)-2-hydroxyiminacetamide 在 sodium nitrate 、 硫酸 作用下， 反应 1.25h， 生成 6-溴-5-硝基靛红
  参考文献：
  名称：

  Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases

  摘要：

  Pharmacological inhibitors of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinases have a promising potential for applications against several neurodegenerative diseases such as Alzheimer's disease. Indirubins, a family of bis-indoles isolated from various natural sources, are potent inhibitors of several kinases, including GSK-3. Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases. This modeling approach provided some insight into the molecular basis of indirubins' action and selectivity and allowed us to forecast some improvements of this family of bis-indoles as kinase inhibitors. Predicted molecules, including 6-substituted and 5,6-disubstituted indirubins, were synthesized and evaluated as CDK and GSK-3 inhibitors. Control, kinase-inactive indirubins were obtained by introduction of a methyl substitution on N1.

  DOI：

  10.1021/jm031016d

文献信息

• [EN] BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE GPR119
  申请人：SCHERING CORP

  公开号：WO2009143049A1

  公开（公告）日：2009-11-26

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及公式（I）的双环杂环衍生物，包含双环杂环衍生物的组合物，以及使用双环杂环衍生物治疗或预防患者的肥胖、糖尿病、代谢紊乱、心血管疾病或与GPR119活性相关的疾病的方法。
• [EN] INDIRUBIN-TYPE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THEIR USE<br/>[FR] COMPOSES DE TYPE INDIRUBINE, COMPOSITIONS ET LEURS PROCEDES D'UTILISATION
  申请人：UNIV ROCKEFELLER

  公开号：WO2005041954A1

  公开（公告）日：2005-05-12

  Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.

  提供了包括6-溴吲哚红、5-氨基吲哚红和N-甲基吲哚红以及相关吲哚红衍生物的化合物和组合物，这些化合物对于选择性调节糖原合酶激酶-3、细胞周期蛋白激酶或芳香烃受体非常有用。利用本发明的化合物提供了抑制或调节细胞生长或细胞周期的方法。在其他方面，提供了用于治疗原虫介导疾病、阿尔茨海默病和糖尿病的化合物和方法。
• Indirubin-Type Compounds, Compositions, and Methods for Their Use
  申请人：Meijer Laurent

  公开号：US20070276025A1

  公开（公告）日：2007-11-29

  Compounds and compositions including 6-bromo-indirubin, 5-amino-indirubin and N-methyl-indirubins and related indirubin derivatives are provided that are useful as selective modulators of glycogen synthase kinase-3, cyclin-dependent protein kinases or aryl hydrocarbon receptors. Methods of inhibiting or modulating cell growth or cell cycling are provided using the compounds of the invention. In other aspects, compounds and methods for the treatment of protozoan-mediated diseases, Alzheimer's disease and diabetes are provided.

  提供了包括6-溴吲哚红、5-氨基吲哚红和N-甲基吲哚红及相关吲哚红衍生物的化合物和组合物，它们可用作选择性调节糖原合酶激酶-3、周期蛋白依赖性蛋白激酶或芳香族羟基化酶的调节剂。使用本发明的化合物提供了抑制或调节细胞生长或细胞周期的方法。在其他方面，提供了治疗原虫介导疾病、阿尔茨海默病和糖尿病的化合物和方法。
• BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS
  申请人：Harris Joel M.

  公开号：US20110065671A1

  公开（公告）日：2011-03-17

  The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.

  本发明涉及式(I)的二环杂环衍生物，包括一种二环杂环衍生物的组合物，并且还涉及使用这些二环杂环衍生物来治疗或预防患者的肥胖症、糖尿病、代谢障碍、心血管疾病或与GPR1 19活性相关的疾病的方法。
• In vitro cytotoxicity evaluation of some substituted isatin derivatives
  作者：Kara L. Vine、Julie M. Locke、Marie Ranson、Stephen G. Pyne、John B. Bremner

  DOI：10.1016/j.bmc.2006.10.035

  日期：2007.1

  A range of substituted 1H-indole-2,3-diones (isatins) were synthesized using standard procedures and their cytotoxicity evaluated against the human monocyte-like histiocytic lymphoma (U937) cell line in vitro. SAR studies identified C-5, C-6, and C-7 substitution greatly enhanced activity with some di- and tri-halogenated isatins giving IC50 values < 10 mu M. Of the 23 compounds tested, four were selected for further screening against a panel of five human cancer cell lines. These compounds, in general, showed greater selectivity toward leukemia and lymphoma cells over breast, prostate, and colorectal carcinoma cell lines. The most active compound, 5,6,7-tribromoisatin (2p), was found to be antiproliferative at low micromolar concentrations and also activated the effector caspases 3 and 7 in a dose-dependent manner. These results indicate that di- and tri-substituted isatins may be useful leads for anticancer drug development in the future. (c) 2006 Elsevier Ltd. All rights reserved.